Literature DB >> 31412267

Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways.

Joseph Yi Zhou1, Anil Poudel2, Ryan Welchko2, Naveen Mekala1, Prashanth Chandramani-Shivalingappa2, Mariana Georgeta Rosca3, Lixin Li4.   

Abstract

Glucagon like peptide-1 (GLP-1) promotes postprandial insulin secretion. Liraglutide, a full agonist of the GLP-1 receptor, reduces body weight, improve insulin sensitivity, and alleviate Non Alcoholic Fatty Liver Disease (NAFLD). However, the underlying mechanisms remain unclear. This study aims to explore the underlying mechanisms and cell signaling pathways involved in the anti-obesity and anti-inflammatory effects of liraglutide. Mice were fed a high fat high sucrose diet to induce diabetes, diabetic mice were divided into two groups and injected with liraglutide or vehicle for 14 days. Liraglutide treatment improved insulin sensitivity, accompanied with reduced expression of the phosphorylated Acetyl-CoA carboxylase-2 (ACC2) and upregulation of long chain acyl CoA dehydrogenase (LCAD) in insulin sensitive tissues. Furthermore, liraglutide induced adenosine monophosphate-activated protein kinase-α (AMPK-α) and Sirtuin-1(Sirt-1) protein expression in liver and perigonadal fat. Liraglutide induced elevation of fatty acid oxidation in these tissues may be mediated through the AMPK-Sirt-1 cell signaling pathway. In addition, liraglutide induced brown adipocyte differentiation in skeletal muscle, including induction of uncoupling protein-1 (UCP-1) and PR-domain-containing-16 (PRDM-16) protein in association with induction of SIRT-1. Importantly, liraglutide displayed anti-inflammation effect. Specifically, liraglutide led to a significant reduction in circulating interleukin-1 β (IL-1 β) and interleukin-6 (IL-6) as well as hepatic IL-1 β and IL-6 content. The expression of inducible nitric oxide synthase (iNOS-1) and cyclooxygenase-2 (COX-2) in insulin sensitive tissues was also reduced following liraglutide treatment. In conclusion, liraglutide improves insulin sensitivity through multiple pathways resulting in reduction of inflammation, elevation of fatty acid oxidation, and induction of adaptive thermogenesis.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adipocyte; Insulin resistance; Liraglutide; Metabolism; Obesity

Mesh:

Substances:

Year:  2019        PMID: 31412267     DOI: 10.1016/j.ejphar.2019.172594

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  15 in total

1.  Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist.

Authors:  Rayane Miranda Pontes-da-Silva; Thatiany de Souza Marinho; Luiz Eduardo de Macedo Cardoso; Carlos Alberto Mandarim-de-Lacerda; Marcia Barbosa Aguila
Journal:  Int J Obes (Lond)       Date:  2021-08-31       Impact factor: 5.095

Review 2.  Sirtuins-Mediated System-Level Regulation of Mammalian Tissues at the Interface between Metabolism and Cell Cycle: A Systematic Review.

Authors:  Parcival Maissan; Eva J Mooij; Matteo Barberis
Journal:  Biology (Basel)       Date:  2021-03-04

Review 3.  PRDM16 Regulating Adipocyte Transformation and Thermogenesis: A Promising Therapeutic Target for Obesity and Diabetes.

Authors:  Na Jiang; Ming Yang; Yachun Han; Hao Zhao; Lin Sun
Journal:  Front Pharmacol       Date:  2022-04-08       Impact factor: 5.988

Review 4.  Endocrine disrupting chemicals: Friend or foe to brown and beige adipose tissue?

Authors:  Cynthia E Francis; Logan Allee; Helen Nguyen; Rachel D Grindstaff; Colette N Miller; Srujana Rayalam
Journal:  Toxicology       Date:  2021-10-02       Impact factor: 4.571

Review 5.  Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?

Authors:  Niki Katsiki; Ele Ferrannini
Journal:  J Diabetes Complications       Date:  2020-08-26       Impact factor: 2.852

6.  Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway.

Authors:  Yunyun Fang; Linlin Ji; Chaoyu Zhu; Yuanyuan Xiao; Jingjing Zhang; Junxi Lu; Jun Yin; Li Wei
Journal:  Front Cell Dev Biol       Date:  2020-11-27

7.  QSHY Granules Promote White Adipose Tissue Browning and Correct BCAAs Metabolic Disorder in NAFLD Mice.

Authors:  Binbin Zhang; Mingzhu Ni; Xiaojing Li; Qiaohong Liu; Yiyang Hu; Yu Zhao
Journal:  Diabetes Metab Syndr Obes       Date:  2021-10-14       Impact factor: 3.168

8.  Metformin alleviates monoamine oxidase-related vascular oxidative stress and endothelial dysfunction in rats with diet-induced obesity.

Authors:  Loredana N Ionică; Laura Gaiță; Anca M Bînă; Raluca Soșdean; Rodica Lighezan; Alexandra Sima; Daniel Malița; Octavian M Crețu; Ovidiu Burlacu; Danina M Muntean; Adrian Sturza
Journal:  Mol Cell Biochem       Date:  2021-07-03       Impact factor: 3.396

9.  Resveratrol Ameliorates High-Fat-Diet-Induced Abnormalities in Hepatic Glucose Metabolism in Mice via the AMP-Activated Protein Kinase Pathway.

Authors:  Caiping Lu; Hanying Xing; Linquan Yang; Kaiting Chen; Linyi Shu; Xiaojian Zhao; Guangyao Song
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-25       Impact factor: 2.629

Review 10.  Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.

Authors:  Baptist Gallwitz; Francesco Giorgino
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-29       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.